Serum levels of angiopoietin-2 are associated with the growth of multiple myeloma

Cancer Investigation

Volumn 31, Issue 6, 2013, Pages 385-389

  Pappa, Constantina A ^a   Tsirakis, George ^b   Samiotakis, Panagiotis ^b   Tsigaridaki, Maria ^b   Alegakis, Athanasios ^c   Goulidaki, Nectaria ^b   Alexandrakis, Michael G ^b,c  

^a Venizelion General Hospital   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^c UNIVERSITY OF CRETE   (Greece)

Author keywords

Angiogenesis; Growth factors; Myeloma; Receptors

Indexed keywords

ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; BETA 2 MICROGLOBULIN; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; INTERLEUKIN 6; LACTATE DEHYDROGENASE; MELPHALAN; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ANGIOPOIETIN-2; BETA 2-MICROGLOBULIN; C-REACTIVE PROTEIN; FEMALE; HUMANS; INTERLEUKIN-6; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; RECEPTOR, TIE-2; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84879488668     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357907.2013.800093     Document Type: Article

References (41)

1. Giuliani N, Colla S, Lazzaretti M, Sala R, Roti G, Mancini C, Bonomini S, Lunghi P, Hojden M, Genestreti G, Svaldi M, Coser P, Fattori P.P, Sammarelli G, Gazzola GC, Bataille R, Almici C, Caramatti C, Mangoni L, Rizzoli V. Proangiogenic properties of human myeloma cells: Production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. Blood 2003;102:638-645 (Pubitemid 36841986)
2. Hideshima T.ChauhanD. Podar, K. Schlossman RL. Richardson P. Anderson KC. Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol 2001;28:607-612 (Pubitemid 33134420)
3. AlexandrakisMG. PassamFJ.Ganotakis E. Dafnis E. DambakiC. Konsolas J. Kyriakou DS. Stathopoulos E. Bonemarrowmicrovascular density and angiogenic growth factors inmultiplemyeloma. Clin Chem Lab Med 2004;42:1122-1126 (Pubitemid 39481152)
4. Kumar S, Witzig TE, Timm M, Haug J, Wellik L, Kimlinger TK. Greipp PR. Rajkumar SV. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: Evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. Blood 2004;104:1159-1165 (Pubitemid 39038038)
5. Alexandrakis M.G. Passam F.H. Sfiridaki A. Kandidaki E. Roussou P. Kyriakou D.S. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: Correlation with markers of disease activity. Am J Hematol 2003;72: 229-233 (Pubitemid 36383972)
6. Sezer O. Jakob C, Eucker J. Niemöller K. Gatz F. Wernecke K. Possinger K. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. Eur J Haematol 2001;66:83-88 (Pubitemid 32154100)
7. Pappa C.A, Tsirakis G, Kanellou P, Kaparou M, Stratinaki M, Xekalou A, Alegakis A, Boula A, Stathopoulos EN, Alexandrakis MG. Monitoring serum levels ELR + CXC chemokines and the relationship between microvessel density and angiogenic growth factors in multiple myeloma. Cytokine 2011;56:616-620
8. Sezer O, Niemöller K, Jakob C, Zavrski I, Heider U, Eucker J, Kaufmann O, Possinger K. Relationship between bone marrow angiogenesis and plasma cell infiltration and serum beta2-microglobulin levels in patients with multiple myeloma. Ann Hematol 2001;80:598-601 (Pubitemid 33062000)
9. Uneda S, Matsuno F. Sonoki T. Tniguchi I. Kawano F. Hata H. Expressions of vascular endothelial growth factor and angiopoietin-2 in myeloma cells. Haematologica 2003;88:113-115 (Pubitemid 36168864)
10. Joshi S, Khan R, Sharma M, Kumar L, Sharma A. Angiopoietin-2: A potential novel diagnostic marker in multiple myeloma. Clin Biochem 2011;44:590-595
11. Scharpfenecker M, Fiedler U, Reiss Y, Augustin HG. The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J Cell Sci 2005;118:771-780 (Pubitemid 40372585)
12. Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD, Glazer N, Holash J, McDonald DM, Yancopoulos GD. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 2000;6:460-463 (Pubitemid 30208166)
13. Sillaber C,Mayerhofer M. Aichberger KJ.KrauthMT.Valent P. Expression of angiogenic factors in chronic myeloid leukaemia: Role of the bcr/abl oncogene, biochemical mechanisms, and potential clinical implications. Eur J Clin Invest 2004;34(Suppl 2):2-11
14. Koh GY. Kim I. Kwak HJ. Yun MJ. Leem JC. Biomedical significance of endothelial cell specific growth factor, angiopoietin. Exp Mol Med 2002;34:1-11 (Pubitemid 34408199)
15. Wong AL, Haroon ZA, Werner S, Dewhirst MW, Greenberg CS, Peters KG. Tie-2 expression and phosphorylation in angiogenic and quiescent adult tissues. Circ Res 1997;81:567-574 (Pubitemid 27432744)
16. Choi K. Kennedy M. Kazarov A. Papadimitriou JC. Keller G. A common precursor for hematopoietic and endothelial cells. Development 1998;125:725-732 (Pubitemid 28108096)
17. Peters KG, Coogan A, Berry D, Marks J, Iglehart JD, Kontos CD, Rao P, Sankar S, Trogan E. Expression of Tie2/TEK in breast tumour vasculature provides a newmarker for evaluation of tumour angiogenesis. Br J Cancer 1998;77:51-56 (Pubitemid 28029772)
18. Yabkowitz R. Meyer S. Black T. Elliott G. Merewether LA. Yamane HK. Inflammatory cytokines and vascular endothelial growth factor stimulate the release of soluble tie receptor from human endothelial cells via metalloprotease activation. Blood 1999;93:1969-1979 (Pubitemid 29128499)
19. Findley CM. Cudmore MJ. Ahmed A. Kontos CD. VEGF induces Tie2 shedding via a phosphoinositide 3-kinase/Akt dependent pathway to modulate Tie2 signaling. Arterioscler Thromb Vasc Biol 2007;27:2619-2626 (Pubitemid 350158914)
20. Quartarone E. Alonci A. Allegra A. Bellomo G. Calabró L. D'Angelo A. Del Fabro V. Grasso A. Cincotta M.Musolino C. Differential levels of soluble angiopoietin-2 and Tie-2 in patients with haematological malignancies. Eur J Haematol 2006;77:480-485 (Pubitemid 44690793)
21. Arai F. Hirao A. Ohmura M. Sato H. Matsuoka S. Takubo K, Ito K. Koh GY. Suda T. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 2004;118:149-161 (Pubitemid 38962572)
22. Anargyrou K, Terpos E, Vassilakopoulos TP, Pouli A, Sachanas S, Tzenou T, Masouridis S, Christoulas D, Angelopoulou MK, Dimitriadou EM, Kalpadakis C, Tsionos K, Panayiotidis P, Dimopoulos MA, Pangalis GA, Kyrtsonis MC. Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib. Haematologica 2008;93:451-454 (Pubitemid 351398649)
23. Lobov IB, Brooks PC, Lang RA. Angiopoietin-2 displays VEGFdependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA 2002;99:11205-11210 (Pubitemid 34920903)
24. Kline M. Donovan K. Wellik L. Lust C. Jin W. Moon-Tasson L. Xiong Y. Witzig TE. Kumar S. Rajkumar SV. Lust JA. Cytokine and chemokine profiles inmultiplemyeloma; significance of stromal interaction and correlation of IL-8 production with disease progression. Leuk Res 2007;31:591-598 (Pubitemid 46559994)
25. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: Clinical applications. Blood 2004;104:607-618 (Pubitemid 38970551)
26. Terpos E,Anargyrou K, Katodritou E, Kastritis E, Papatheodorou A, Christoulas D, Pouli A, Michalis E, Delimpasi S, Gkotzamanidou M, Nikitas N, Koumoustiotis V, Margaritis D, Tsionos K, Stefanoudaki E, Meletis J, Zervas K, Dimopoulos MA. Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents. Int J Cancer 2012;130:735-742
27. Schliemann C, Bieker R, Padro T, Kessler T, Hintelmann H, Buchner T, Berdel WE, Mesters RM. Expression of angiopoietins and their receptor Tie2 in the bone marrow of patients with acute myeloid leukemia. Haematologica 2006;91:1203-1211 (Pubitemid 44408430)
28. Martinelli S, Maffei R, Castelli I, Santachiara R, Zucchini P, Fontana M, Bonacorsi G, Leonardi G, Marasca R, Torelli G. Increased expression of angiopoietin-2 characterizes early B-cell chronic lymphocytic leukemia with poor prognosis. Leuk Res 2008;32:593-597 (Pubitemid 351248968)
29. Terpos E, Kastritis E, Roussou M, Heath D, Christoulas D, Anagnostopoulos N, Eleftherakis-Papaiakovou E, Tsionos K, Croucher P, Dimopoulos MA. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia 2008;22:2247-2256
30. Bhaskar A. GuptaR.Vishnubhatla S.Kumar L. Sharma A. Sharma MC. Das P.Thakur SC.Angiopoietins as biomarker of disease activity and response to therapy in multiple myeloma. Leuk Lymphoma 2012;Nov 26. doi: 10.3109/10428194.2012.745523. [Epub ahead of print]
31. Akkök CA, Hervig T, Stamnesfet S, Nesthus I,Melve GK, Lassalle P, Bruserud O. Effects of peripheral blood stem cell apheresis on systemic cytokine levels in patients with multiple myeloma. Cytotherapy 2011;13:1259-1268
32. Dankbar B, Padŕo T, Leo R, Feldmann B, Kropff M, Mesters RM, Serve H, BerdelWE, Kienast J. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000;95:2630-2636 (Pubitemid 30210543)
33. Anderson KC. Moving disease biology from the laboratory to the clinic. Semin Oncol 2002;29:17-20
34. Bhaskar A. Gupta R. Sreenivas V. Rani L. Kumar L. Sharma A. SharmaOD. SharmaMC. Thakur SC. Synergistic effect of vascular endothelial growth factor and angiopoietin-2 on progression free survival in multiple myeloma. Leuk Res 2013;37:410-415
35. Dimopoulos MA. Barlogie B. Smith TL. Alexanian R. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med 1991;115:931-935
36. Kyrstsonis MC. Dedoussis G. Baxevanis C. Stamatelou M. Maniatis A. Serum interleukin-6 (IL-6) and interleukin-4 (IL-4) in patients with multiple myeloma (MM). Br J Haematol 1996;92:420-422 (Pubitemid 26042937)
37. Bataille R, Boccadoro M, Klein B, Durie B, Pileri A. Creactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood 1992;80: 733-737
38. Harris AL, Reusch P, Barleon B, Hang C, Dobbs N,Marme D. Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy. Clin Cancer Res 2001;7:1992-1997 (Pubitemid 32994837)
39. Chung NAY,Makin AJ, Lip GYH.Measurement of the soluble angiopoietin receptor tie-2 in patients with coronary artery disease: Development andapplicationof an immunoassay. Eur J Clin Invest 2003;33:529-535 (Pubitemid 36783211)
40. Chong AY, Caine GJ, Freestone B, Blann AD, Lip GY. Plasma angiopoietin-1, angiopoietin-2, and angiopoietin receptor tie-2 levels in congestive heart failure. J Am Coll Cardiol 2004;43:423-428 (Pubitemid 38167703)
41. Findley CM, Cudmore MJ, Ahmed A, Kontos CD. VEGF induces Tie2 shedding via a phosphoinositide 3-kinase/Akt dependent pathway to modulate Tie2 signaling. Arterioscler Thromb Vasc Biol 2007;27:2619-2626 (Pubitemid 350158914)